遗传资源

一例ISPD基因复合杂合变异所致的肢带型肌营养不良症2U型的诊断和基因检测分析

展开
  • 1.福建省儿童医院心内科,福州 350011
    2.福建省妇幼保健院儿科,福州 350001
    3.上海交通大学医学院附属上海儿童医学中心心内科,上海 200127
黄娟,硕士研究生,住院医师,研究方向:临床医学(心血管)。E-mail: 451294832@qq.com;|缪文华,硕士研究生,住院医师,研究方向:临床儿科学(心血管)。E-mail: 36163193@qq.com;
黄娟和缪文华并列第一作者。

收稿日期: 2023-02-15

  修回日期: 2023-05-10

  网络出版日期: 2023-05-19

基金资助

福建省自然科学基金面上项目(2022J011072)

Diagnosis and genetic testing analysis of limb-girdle muscular dystrophy type 2U caused by a compound heterozygous mutation in the ISPD gene

Expand
  • 1. Division of Cardiology, Fujian Children’s Hospital, Fuzhou 350011, China
    2. Pediatrics, Fujian Maternity and Child Health Hospital, Fuzhou 350001, China
    3. Division of Cardiology, Shanghai Children’s Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200127, China

Received date: 2023-02-15

  Revised date: 2023-05-10

  Online published: 2023-05-19

Supported by

General Program of Natural Science Foundation of Fujian(2022J011072)

摘要

肢带型肌营养不良症(limb-girdle muscular dystrophy,LGMD)是一组罕见的非先天性遗传性肌肉疾病,主要表现为四肢近端肌张力及肌力进行性减退,其临床表现及遗传模式具有异质性。本研究报道了1例肢带型肌营养不良症2U型10岁男性患者,运动后出现双下肢肌肉无力,入院查肌酸激酶明显升高,经水化碱化治疗后无效。利用高通量测序方法对患者及其父母、妹妹进行肌营养不良相关基因检测,该患者存在ISPD基因外显子9杂合缺失以及c.1231C>T(p.Leu411Phe)的杂合错义变异,其父亲携带ISPD基因c.1231C>T(p.Leu411Phe)的杂合错义变异,母亲及妹妹携带ISPD基因外显子9杂合缺失,上述变异在现有的数据库及文献中均未见报道。对变异位点的保守性分析和蛋白结构预测分析表明,上述位点保守性高,且均位于ISPD蛋白C端结构域,可能对蛋白功能产生影响。综合以上结果并结合相关临床资料,可明确诊断该患者为肢带型肌营养不良症2U型。本文通过总结该患者临床特点及对ISPD基因新变异进行分析,丰富了ISPD基因变异谱,有助于该病早期诊断及遗传咨询。

本文引用格式

黄娟, 缪文华, 郭晓峰, 吉炜 . 一例ISPD基因复合杂合变异所致的肢带型肌营养不良症2U型的诊断和基因检测分析[J]. 遗传, 2023 , 45(6) : 536 -542 . DOI: 10.16288/j.yczz.22-329

Abstract

Limb-girdle muscular dystrophy (LGMD), a rare group of non-congenital inherited muscle diseases, is characterized by a progressive reduction in muscle tone and force of the proximal limbs. The clinical manifestations and genetic patterns of LGMD are heterogeneous. This study reported on a 10-year-old male patient with LGMD type 2U who experienced muscle weakness in the lower limbs after exercise. Upon admission, the patient's creatine kinase levels were significantly elevated, and hydration and alkalinization therapy were ineffective. Using high-throughput sequencing, muscular dystrophy-related genes were tested in the patient, his parents, and his sister. The patient was found to have a heterozygous deletion of exon 9 of the ISPD gene and a heterozygous missense mutation c.1231C>T (p.Leu411Phe). The patient's father carried the heterozygous missense mutation c.1231C>T (p.Leu411Phe) of the ISPD gene, while his mother and sister carried a heterozygous deletion of exon 9 of the ISPD gene. These mutations have not been reported in existing databases or literature. Conservation and protein structure prediction analyses of the mutation sites indicated that they are highly conserved and located in the C-terminal domain of the ISPD protein, which may affect protein function. Based on the above results and relevant clinical data, the patient was definitively diagnosed with LGMD type 2U. This study enriched the spectrum of ISPD gene mutations by summarizing the patient's clinical characteristics and analyzing new ISPD gene variations. This can aid in the early diagnosis and genetic counseling of the disease.

参考文献

[1] Wicklund MP, Kissel JT. The limb-girdle muscular dystrophies. Neurol Clin, 2014, 32(3): 729-749.
[2] Liewluck T, Milone M. Untangling the complexity of limb-girdle muscular dystrophies. Muscle Nerve, 2018, 58(2): 167-177.
[3] Chu M L, Ellen M. The limb-girdle muscular dystrophies: is treatment on the horizon? Neurotherapeutics, 2018, 15(4): 849-862.
[4] Cirak S, Foley AR, Herrmann R, Willer T, Yau S, Stevens E, Torelli S, Brodd L, Kamynina A, Vondracek P, Roper H, Longman C, Korinthenberg R, Marrosu G, Nürnberg P, Consortium U, Michele DE, Plagnol V, Hurles M, Moore SA, Sewry CA, Campbell KP, Voit T, Muntoni F. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain, 2013, 136(Pt 1): 269-281.
[5] Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC consortium on limb-girdle dystrophies. Neuromuscul Disord, 1995, 5(1): 71-74.
[6] Angelini C. LGMD. Identification, description and classification. Acta Myol, 2020, 39(4): 207-217.
[7] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 2015, 17(5): 405-424.
[8] Luo SS, Lu JH. Limb-girdle muscular dystrophy. Chin J Neurol, 2019, 52(7): 573-581.
[8] 罗苏珊, 卢家红. 肢带型肌营养不良. 中华神经科杂志, 2019, 52(7): 573-581.
[9] Muntoni F, Brockington M, Blake DJ, Torelli S, Brown SC. Defective glycosylation in muscular dystrophy. Lancet, 2002, 360(9343): 1419-1421.
[10] Waite A, Brown SC, Blake DJ. The dystrophin- glycoprotein complex in brain development and disease. Trends Neurosci, 2012, 35(8): 487-496.
[11] Yang H Y, Cai F, Liao H G, Gan S Y, Xiao T, Wu L W. Case report: ISPD gene mutation leads to dystroglycanopathies: genotype phenotype analysis and treatment exploration. Front Pediatr, 2021, 9: 710553.
[12] Turan S, Farruggio AP, Srifa W, Day JW, Calos MP. Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy. Mol Ther, 2016, 24(4): 685-696.
[13] Pedemonte N, Lukacs GL, Kai D, Caci E, Zegarra-Moran O, Galietta LJV, Verkman AS. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest, 2005, 115(9): 2564.
[14] Carotti M, Marsolier J, Soardi M, Bianchini E, Gomiero C, Fecchio C, Henriques SF, Betto R, Roberta Sacchetto R, Richard L, Sandonà D. Repairing folding-defective a-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D. Hum Mol Genet, 2018, 27(6): 969-984.
[15] Riemersma M, Froese DS, van Tol W, Engelke UF, Kopec J, van Scherpenzeel M, Ashikov A, Krojer T, von Delft F, Tessari M, Buczkowska A, Swiezewska E, Jae LT, Brummelkamp TR, Manya H, Endo T, van Bokhoven H, Yue WW, Lefeber DJ. Human ISPD is a cytidyltransferase required for dystroglycan O-mannosylation. Chem Biol, 2015, 22(12): 1643-1652.
文章导航

/